M-Spike of 0.3 g/dL: Likely MGUS Requiring Risk Stratification and Surveillance
An M-spike of 0.3 g/dL (3 g/L) with otherwise normal values most likely represents monoclonal gammopathy of undetermined significance (MGUS), and you should obtain additional testing to risk-stratify this patient, then implement surveillance based on their risk category.
Initial Diagnostic Workup
You need to complete the following tests immediately to confirm MGUS and exclude active myeloma:
- Serum free light chain (FLC) assay with ratio - this is critical for risk stratification
- Immunofixation electrophoresis - to determine the immunoglobulin isotype (IgG, IgA, or IgM)
- Complete blood count - to exclude anemia
- Serum creatinine and calcium - to exclude renal insufficiency and hypercalcemia
- Bone marrow biopsy is NOT needed if all other parameters are normal, as the M-protein is well below 30 g/L
The diagnosis of MGUS requires: M-protein <30 g/L, <10% clonal plasma cells in bone marrow, and absence of end-organ damage (no CRAB criteria: hypercalcemia, renal insufficiency, anemia, or bone lesions) 1.
Risk Stratification Using Mayo Clinic Model
Once you have the isotype and FLC ratio, classify the patient using the Mayo Clinic risk stratification model 2, 1:
Low-risk MGUS (all three criteria must be present):
- IgG isotype
- M-protein <15 g/L (<1.5 g/dL)
- Normal FLC ratio
Intermediate-risk MGUS: One or two risk factors present
High-risk MGUS: All three risk factors abnormal (non-IgG, M-protein ≥15 g/L, abnormal FLC ratio)
The 20-year progression risk is 5% for low-risk, 21% for low-intermediate, 37% for high-intermediate, and 58% for high-risk MGUS 2.
Surveillance Protocol Based on Risk
For Low-Risk MGUS:
- Repeat testing at 6 months
- If stable, follow every 1-2 years 2
- Alternatively, some guidelines suggest every 2-3 years if stable 1
For Intermediate or High-Risk MGUS:
For patients with life expectancy <5 years:
- No routine follow-up is needed; only investigate if symptoms develop 2
What to Monitor at Each Visit
At each surveillance visit, assess for:
- Symptoms suggesting progression: bone pain, fatigue, weight loss, recurrent infections, bleeding
- Physical examination findings: pallor, bone tenderness, hepatosplenomegaly
- Laboratory studies:
- Quantify M-protein by serum protein electrophoresis
- Complete blood count
- Creatinine and calcium
- If FLC ratio was abnormal initially, also monitor NT-pro-BNP and urinary albumin to detect light chain organ damage 2
Important Clinical Caveats
The overall risk of progression is approximately 1% per year 1, meaning this patient has a lifelong but relatively low absolute risk of developing multiple myeloma or related disorders.
Quantification precision matters: At this low M-protein concentration (0.3 g/dL), there is significant inter-laboratory variability in quantification 3, 4. The biological coefficient of variation for M-proteins is approximately 8%, and reference change values suggest that changes of 36-40% are needed to represent true biological change 5, 6. Therefore, always monitor this patient at the same laboratory to ensure accurate trend assessment.
No preventive interventions exist: There are currently no treatments to prevent or delay MGUS progression, so intervention should only occur in clinical trials 2.
Patient education is essential: Instruct the patient to contact you immediately if they develop symptoms suggestive of progression (bone pain, fatigue, infections, bleeding), rather than waiting for the next scheduled visit 2.